妊娠期亚临床甲状腺功能减退症妇女的甲状腺激素治疗:美国全国性评估
该回顾性队列研究利用2010年1月1日至2014年12月31日美国大型行政数据库,纳入5405例未治疗时TSH 2.5-10 mIU/L的亚临床甲减孕妇,其中843例接受甲状腺激素治疗(治疗前平均TSH 4.8 mIU/L),4562例未治疗(基线平均TSH 3.3 mIU/L)。治疗组流产发生率10.6%(89例),低于未治疗组的13.5%(614例);校正后治疗组流产风险降低(OR 0.62,95%CI 0.48-0.82),但早产(OR 1.60,95%CI 1.14-2.24)、妊娠期糖尿病(OR 1.37,95%CI 1.05-1.79)和先兆子痫(OR 1.61,95%CI 1.10-2.37)风险升高。按治疗前TSH分层,TSH 4.1-10 mIU/L者治疗与流产风险降低相关(OR 0.45,95%CI 0.30-0.65),而TSH 2.5-4.0 mIU/L者无显著关联(OR 0.91,95%CI 0.65-1.23)。作者认为甲状腺激素治疗与亚临床甲减孕妇流产风险降低相关,尤其治疗前TSH 4.1-10 mIU/L者,但其他妊娠相关不良结局风险升高,需进一步研究评估该人群甲状腺激素治疗的安全性。
要点
- 亚临床甲减孕妇(未治疗TSH 2.5-10 mIU/L)接受甲状腺激素治疗与流产风险降低相关(OR 0.62,95%CI 0.48-0.82)。
- 治疗前TSH 4.1-10 mIU/L者治疗与流产风险降低相关(OR 0.45,95%CI 0.30-0.65);TSH 2.5-4.0 mIU/L者无显著关联(OR 0.91,95%CI 0.65-1.23)。
- 治疗组早产风险升高(OR 1.60,95%CI 1.14-2.24)、妊娠期糖尿病风险升高(OR 1.37,95%CI 1.05-1.79)、先兆子痫风险升高(OR 1.61,95%CI 1.10-2.37)。
- 治疗组与未治疗组其他妊娠相关不良结局相似。
- 作者认为需进一步研究评估该人群甲状腺激素治疗的安全性(原文结论)。
适用人群与场景
- 妊娠妇女,未治疗时甲状腺刺激素(TSH)浓度2.5-10 mIU/L定义为亚临床甲状腺功能减退症。
- 纳入2010年1月1日至2014年12月31日美国大型行政数据库中的5405例亚临床甲减孕妇。
诊断标准与关键阈值
- 亚临床甲状腺功能减退症定义:未治疗时TSH浓度2.5-10 mIU/L。
研究设计与关键结果
- 研究类型:回顾性队列研究;数据库:美国大型行政数据库,时间2010年1月1日至2014年12月31日;样本量:5405例亚临床甲减孕妇。
- 治疗组843例,治疗前平均TSH 4.8(SD 1.7)mIU/L;未治疗组4562例,基线平均TSH 3.3(SD 0.9)mIU/L(P<0.01)。
- 流产发生率:治疗组10.6%(89例)vs 未治疗组13.5%(614例)(P<0.01);校正后OR 0.62(95%CI 0.48-0.82)。
- 与未治疗组相比,治疗组早产OR 1.60(95%CI 1.14-2.24)、妊娠期糖尿病OR 1.37(95%CI 1.05-1.79)、先兆子痫OR 1.61(95%CI 1.10-2.37);其他妊娠相关不良结局两组相似。
- 按治疗前TSH分层:TSH 4.1-10 mIU/L者治疗组 vs 未治疗组流产校正OR 0.45(95%CI 0.30-0.65);TSH 2.5-4.0 mIU/L者OR 0.91(95%CI 0.65-1.23)(P<0.01)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于妊娠期亚临床甲减(未治疗TSH 2.5-10 mIU/L)妇女,甲状腺激素治疗与流产风险降低相关,尤其治疗前TSH 4.1-10 mIU/L者;但治疗组早产、妊娠期糖尿病和先兆子痫风险升高,作者认为需进一步研究评估该人群甲状腺激素治疗的安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism.
DESIGN: Retrospective cohort study.
SETTING: Large US administrative database between 1 January 2010 and 31 December 2014.
PARTICIPANTS: 5405 pregnant women with subclinical hypothyroidism, defined as untreated thyroid stimulating hormone (TSH) concentration 2.5-10 mIU/L.
EXPOSURE: Thyroid hormone therapy.
MAIN OUTCOME MEASURE: Pregnancy loss and other pre-specified maternal and fetal pregnancy related adverse outcomes.
RESULTS: Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment TSH concentration of 4.8 (SD 1.7) mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 (SD 0.9) mIU/L were not treated (P<0.01). Pregnancy loss was significantly less common among treated women (n=89; 10.6%) than among untreated women (n=614; 13.5%) (P<0.01). Compared with the untreated group, treated women had lower adjusted odds of pregnancy loss (odds ratio 0.62, 95% confidence interval 0.48 to 0.82) but higher odds of preterm delivery (1.60, 1.14 to 2.24), gestational diabetes (1.37, 1.05 to 1.79), and pre-eclampsia (1.61, 1.10 to 2.37); other pregnancy related adverse outcomes were similar between the two groups. The adjusted odds of pregnancy loss were lower in treated women than in untreated women if their pre-treatment TSH concentration was 4.1-10 mIU/L (odds ratio 0.45, 0.30 to 0.65) but not if it was 2.5-4.0 mIU/L (0.91, 0.65 to 1.23) (P<0.01).
CONCLUSION: Thyroid hormone treatment was associated with decreased risk of pregnancy loss among women with subclinical hypothyroidism, especially those with pre-treatment TSH concentrations of 4.1-10 mIU/L. However, the increased risk of other pregnancy related adverse outcomes calls for additional studies evaluating the safety of thyroid hormone treatment in this patient population.
参考来源
- Maraka S, Mwangi R, McCoy RG, et al. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. BMJ. 2017. PMID: 28122781. doi:10.1136/bmj.i6865
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。